SOPHIA HOLDINGS (6942) FY2026 Q3 Earnings Report

Financial Highlights

• Net Sales: ¥6.14B
• Operating Income: ¥79M
• Net Income: ¥36M
• EPS: ¥7.88

Income Statement

Balance Sheet

Cash Flow Statement

Profitability Ratios

Year-over-Year Comparison

Share Information

Dividend Information

Segment Information

Full Year Forecast

---

AI Financial Analysis

Executive Summary

FY2026 Q3 cumulative performance was weak, with modest revenue contraction compounded by the absence of the prior-year disposal gain and weaker segment profits. Revenue declined 2.8% YoY to ¥6.145bn. Operating income fell 89.8% YoY to ¥79m, while profit attributable to owners declined 84.4% to ¥36m. The operating margin compressed by 1,089bp to 1.3% from 12.2% a year earlier. The net profit margin contracted by 311bp to 0.6% from 3.7%. Gross margin declined by 112bp to 36.1%, reflecting a ¥134m reduction in gross profit despite only a ¥175m revenue decline. SG&A expense increased 1.9% YoY to ¥2.157bn, causing the SG&A-to-revenue ratio to rise by 162bp to 35.1%. The primary cause of the operating-profit decline was other income falling to ¥16m from ¥531m in the prior year, when the company booked a ¥513m gain on the sale of shares in an affiliate. Segment profit before corporate and consolidation adjustments declined 7.8% to ¥453m, indicating that earnings also weakened at the underlying business level, though far less sharply than reported operating income. Net finance income improved to ¥48m from a net finance cost of ¥17m in the prior year, partially cushioning the operating decline. The effective tax rate was elevated at 56.7%, reducing the tax burden factor to 0.434 and further limiting conversion of pre-tax income into net income. The annualized ROE was only 1.6%, with the 0.6% net margin being the principal constraint. The quality alert for low operating efficiency is justified: a 1.3% EBIT margin leaves little buffer against cost inflation or revenue volatility. The quality alert for ROIC of 1.7% is also material, as returns remain below typical capital-cost and 5% minimum efficiency benchmarks. Management retained its full-year forecast, but Q3 cumulative operating income represents only 41.7% of the ¥189m full-year target and net income only 38.7% of the ¥93m target, both materially below the standard 75% Q3 progress rate. Achieving the forecast therefore requires a substantial Q4 earnings recovery, particularly in operating profit.

Profitability Analysis

The annualized DuPont ROE is 1.6%, comprising a 0.6% net profit margin, annualized asset turnover of 1.186x, and financial leverage of 2.26x. The low net margin is the dominant limitation on shareholder returns, rather than asset utilization or leverage. EBIT margin was 1.3%, well below the 5% concern threshold, and declined from 12.2% in the prior-year period. Gross margin declined to 36.1% from 37.3%, a 112bp contraction. SG&A grew 1.9% despite a 2.8% decline in revenue, demonstrating negative operating leverage; SG&A absorbed 35.1% of revenue compared with 33.5% a year earlier. The reported operating-profit collapse principally reflects the non-recurrence of the ¥513m prior-year gain on sale of an affiliate investment, which was included in other income and in corporate adjustments rather than segment operating performance. Excluding this item, the comparison still indicates pressure, as segment profit declined from ¥495m to ¥453m. The core business by segment profit contribution was the dispensing pharmacy and related business, generating ¥402m of segment profit, or approximately 89% of aggregate segment profit before adjustments. Pharmacy revenue was broadly stable at ¥5.179bn, down 0.6% YoY, but segment profit declined 14.8% to ¥402m and its margin fell to 7.8% from 9.1%. Internet-related revenue declined 19.6% to ¥804m and segment profit declined 40.6% to ¥38m, with margin falling to 4.8% from 6.4%. Telecommunications revenue increased 57.9% to ¥162m and segment profit improved to ¥22m from a ¥5m loss, raising the segment margin to 13.4%. The telecommunications turnaround is positive but remains small relative to the pharmacy business. Consolidated corporate and adjustment costs were ¥374m, compared with a ¥275m positive adjustment in the prior-year period, overwhelmingly due to the absence of the prior-year investment-sale gain. The improvement in net finance income supported pre-tax profit, but it cannot offset the low level of recurring operating earnings. The tax burden alert is warranted because the 56.7% effective tax rate is materially above a normal corporate tax range and reduced net-income conversion.

Growth Assessment

Revenue declined 2.8% YoY to ¥6.145bn, with the decline concentrated in the internet-related business. The pharmacy business remained the principal revenue base, accounting for approximately 84% of consolidated revenue, but its revenue was marginally lower and profit contracted at a faster rate. Internet-related business revenue fell by ¥196m YoY, while its segment profit fell by ¥26m, indicating weakened operating leverage. The telecommunications business expanded revenue by ¥59m and returned to profitability, but its scale remains insufficient to offset pressure in the larger businesses. Consolidated gross profit declined ¥134m, while SG&A increased ¥41m, which explains underlying margin compression even before considering non-recurring items. The current-year operating result contains only ¥16m of other income, versus ¥531m in the comparable period; consequently, current profitability provides a cleaner representation of the recurring earnings base than the prior-year headline profit. The acquisition of Security Agent by the internet-related subsidiary during Q3 broadens the group’s internet-related operations, but it also increases execution requirements around integration and realization of expected operating benefits. Full-year revenue guidance of ¥8.342bn implies Q3 cumulative progress of 73.7%, broadly close to the 75% seasonal benchmark. In contrast, the operating-income progress rate is 41.7%, 33.3 percentage points below the benchmark. Net-income progress is 38.7%, 36.3 percentage points below the benchmark. The unchanged forecast therefore embeds a Q4 operating-income requirement of ¥110m and net-income requirement of ¥57m. This required Q4 operating income exceeds the cumulative Q1-Q3 operating income of ¥79m, making delivery highly dependent on a sharp improvement in quarterly profitability and/or timing of earnings recognition.

Financial Health

Liquidity is acceptable, supported by ¥1.844bn of cash and cash equivalents. The current ratio is approximately 1.48x, below the 1.5x healthy benchmark but above the 1.0x warning threshold. The quick ratio is approximately 1.21x, supported by cash and trade receivables, and indicates that short-term obligations are coverable without reliance on inventory sales. Current assets of ¥3.777bn exceed current liabilities of ¥2.550bn by ¥1.227bn. Trade payables of ¥1.782bn are the largest current-liability component, while trade receivables stand at ¥1.228bn and inventories at ¥563m. Short-term bonds and borrowings declined by ¥320m from fiscal year-end to ¥449m, reducing near-term refinancing exposure. Non-current bonds and borrowings also decreased by ¥268m to ¥625m. Lease liabilities total ¥700m, including ¥117m current and ¥583m non-current, and should be considered alongside borrowings when evaluating fixed financial commitments. Total interest-bearing borrowings and lease liabilities are approximately ¥1.773bn, equivalent to about 57.9% of equity. The reported debt-to-equity ratio is 1.26x, below the 2.0x aggressive-financing warning threshold. Total liabilities declined by ¥581m from fiscal year-end to ¥3.848bn, while equity increased by ¥34m to ¥3.063bn. The equity ratio improved to 44.3% from 40.6%, indicating a modest strengthening in balance-sheet capitalization. Goodwill of ¥1.805bn represents 26.1% of total assets and 59.0% of equity. This exceeds the 50% goodwill-to-equity warning threshold and makes a meaningful portion of book equity dependent on the retention of acquired-business value. As the company reports under IFRS, goodwill is not routinely amortized; it is instead subject to impairment testing, increasing the significance of future cash-flow performance in acquired operations.

Notable B/S Changes

Cash and cash equivalents: -¥903m (-32.9%) from fiscal year-end to ¥1.844bn - liquidity declined, alongside substantial repayment of borrowings. Current bonds and borrowings: -¥320m (-41.6%) to ¥449m - materially reduced near-term refinancing exposure. Non-current bonds and borrowings: -¥268m (-30.0%) to ¥625m - continued deleveraging improved capital structure. Goodwill: +¥30m (+1.7%) to ¥1.805bn - acquired-business exposure remains substantial at 59.0% of equity; impairment performance should be monitored. Right-of-use assets: +¥90m (+17.6%) to ¥602m - increased leased-asset base corresponds with lease liabilities of ¥700m. Income taxes receivable: +¥109m to ¥111m - tax-related current assets increased materially while income taxes payable declined. Total liabilities: -¥581m (-13.1%) to ¥3.848bn - reduction in borrowings and tax payables contributed to improvement in the equity ratio to 44.3%.

Cash Flow Quality

Cash and cash equivalents declined by ¥903m from ¥2.747bn at fiscal year-end to ¥1.844bn at Q3. This cash reduction occurred alongside repayment of ¥320m in current borrowings and ¥268m in non-current borrowings, indicating that debt reduction was an important use of liquidity. Cash also remained sufficient to cover total current borrowings of ¥449m by more than four times. Trade receivables increased by ¥84m from fiscal year-end, while inventories increased by ¥12m and trade payables increased by ¥47m. The receivables increase modestly absorbed working capital, although the corresponding payable increase partly mitigated the effect. Income taxes receivable increased to ¥111m from ¥2m, while income taxes payable fell to ¥8m from ¥192m, representing a substantial shift in tax-related working-capital balances. The low level of reported net income means that sustained cash retention and careful working-capital management are particularly important. The business should be monitored for whether Q4 profit recovery converts into cash after receivable collection, inventory management, tax settlements and debt-service requirements.

Dividend Sustainability

The company disclosed a Q2 dividend per share of ¥0 and forecasts a full-year dividend per share of ¥0. Accordingly, there is no current dividend cash commitment or dividend payout burden on earnings and liquidity. Retained earnings increased by ¥36m during the Q3 cumulative period to ¥1.050bn, consistent with the retention of the period’s profit. The absence of dividends preserves financial flexibility while profitability is depressed and goodwill exposure remains elevated. The forecast full-year EPS is ¥19.88, compared with Q3 cumulative EPS of ¥7.88, so retained earnings growth remains dependent on the implied Q4 earnings recovery. Treasury shares were broadly unchanged at approximately ¥62m, and no share-buyback cash commitment is indicated by the disclosed share data. Future distribution capacity should be evaluated primarily against recurring operating-profit recovery, cash retention after debt repayments, and the need to preserve capital against potential goodwill impairment.

Risk Assessment

Business risks include Pharmacy and related operations are the core earnings contributor, but segment profit declined 14.8% YoY despite broadly stable revenue; continued margin pressure in this business would have a disproportionate effect on group profitability., Internet-related revenue declined 19.6% YoY and segment profit fell 40.6%, creating risk that weaker project demand, utilization or pricing persists., The telecommunications segment returned to profitability and expanded revenue strongly, but its small scale means it currently provides limited protection against weakness in pharmacy and internet-related operations., The Q3 acquisition of Security Agent adds integration, customer-retention and execution risk within the internet-related business., For the pharmacy business, reimbursement conditions, drug-pricing revisions, pharmacist labor availability and local competitive intensity are industry-specific risks to margins..

Financial risks include The 1.3% EBIT margin provides limited protection against revenue declines, personnel-cost increases or procurement-cost inflation., The effective tax rate of 56.7% materially reduced earnings conversion, producing a tax burden factor of 0.434., Goodwill of ¥1.805bn equals 59.0% of equity, exceeding the stated warning threshold; under IFRS, adverse performance in acquired businesses could result in impairment charges., Cash declined by ¥903m during the period, although debt balances also decreased and liquidity ratios remain above warning levels., Lease liabilities of ¥700m add fixed contractual obligations to the group’s borrowings..

Key concerns include High likelihood/high impact: FY2026 guidance requires a pronounced Q4 recovery, with only 41.7% operating-income progress against the full-year target at the end of Q3., High likelihood/high impact: recurring profitability is substantially below the prior-year headline level after removal of the ¥513m affiliate-share sale gain., Medium likelihood/high impact: the concentration of goodwill relative to equity increases sensitivity of book value and future earnings to impairment testing., Medium likelihood/medium impact: SG&A rose while revenue declined, and reversal of this negative operating leverage is necessary for sustainable margin recovery., Medium likelihood/medium impact: ROIC of 1.7% indicates that current earnings do not yet generate an adequate return on the capital deployed in operations and acquisitions..

Investment Implications

Key takeaways include Revenue was relatively resilient at -2.8% YoY, but operating income fell 89.8% because prior-year other income did not recur and underlying segment profitability also declined., The pharmacy business remains the core earnings base, but its segment margin fell from 9.1% to 7.8%., Telecommunications showed the strongest operational improvement, moving from a segment loss to a ¥22m profit on 57.9% revenue growth., The balance sheet improved through lower liabilities and a higher 44.3% equity ratio, but goodwill remains elevated at 59.0% of equity., The unchanged full-year forecast requires a material Q4 earnings acceleration and is therefore a central execution measure..

Metrics to watch include Q4 operating income versus the ¥110m implied requirement to achieve the ¥189m full-year forecast, Pharmacy segment revenue growth and segment margin recovery, Internet-related business revenue, utilization and segment-profit trend, Telecommunications segment profitability following its return to profit, SG&A-to-revenue ratio and consolidated EBIT-margin recovery, Cash balance, receivables collection, tax-related balance movements and borrowings repayment, Goodwill impairment testing assumptions and performance of acquired internet-related operations, Effective tax rate normalization and conversion of pre-tax income into net income.

Regarding relative positioning, The group currently combines a defensible, large pharmacy revenue base with smaller IT and telecommunications activities, but its annualized ROE of 1.6%, ROIC of 1.7% and 1.3% EBIT margin place profitability below standard efficiency benchmarks. The telecommunications turnaround is constructive, while the scale and margin pressure in the pharmacy and internet-related businesses remain the decisive determinants of group earnings.